Paul Tudor Jones Bei Gene, Ltd. Transaction History

Tudor Investment Corp Et Al

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$179.87 - $225.13 $287,792 - $360,208	1,600 New	1,600 $287,000
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $103,067 - $158,151	782 Added 48.33%	2,400 $324,000
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $195,955 - $349,568	1,618 New	1,618 $262,000
Q1 2020 May 15, 2020	SELL	$121.84 - $173.19 $156,320 - $222,202	-1,283 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$115.78 - $208.34 $148,545 - $267,300	1,283 New	1,283 $213,000

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.